Will Gilead Sciences continue to stand alone, or will it fall prey to buyout like its neighbors Chiron and Genentech? The company is dominant in the HIV market and is also exploring hear and lung disease treatments. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments